Tissue engineering of cartilage; can cannabinoids help?

Pharmaceuticals

Volumn 3, Issue 9, 2010, Pages 2970-2985

  Gowran, Aoife ^a   McKayed, Katey ^a   Kanichai, Manoj ^a   White, Cillian ^a   Hammadi, Nissrin ^a   Campbell, Veronica ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cannabinoid receptors; Cartilage; Mesenchymal stem cells; Osteoarthritis; Phytocannabinoids

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AGGRECAN; AJULEMIC ACID; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; COLLAGEN TYPE 2; COLLAGENASE; DEXANABINOL; MATRIX METALLOPROTEINASE; PROTEOGLYCAN; TETRAHYDROCANNABINOLIC ACID;

ANTIINFLAMMATORY ACTIVITY; CARTILAGE CELL; CELL DIFFERENTIATION; CELL METABOLISM; CELL MIGRATION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CHONDROGENESIS; CHONDROPATHY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HISTOLOGY; HOMEOSTASIS; HUMAN; IMMUNOFLUORESCENCE; INTERMETHOD COMPARISON; MESENCHYMAL STEM CELL; NONHUMAN; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TISSUE DEGENERATION; TISSUE ENGINEERING; TISSUE REPAIR;

EID: 77957265395     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3092970     Document Type: Review

References (79)

1. Idris, A.I.; van 't Hof, R.J.; Greig, I.R.; Ridge, S.A.; Baker, D.; Ross, R.A.; Ralston, S.H. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. 2005, 11, 774-779.
2. Ofek, O.; Karsak, M.; Leclerc, N.; Fogel, M.; Frenkel, B.; Wright, K.; Tam, J.; Attar-Namdar, M.; Kram, V.; Shohami, E.; Mechoulam, R.; Zimmer, A.; Bab, I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. USA 2006, 103, 696-701.
3. Idris, A.I.; Ralston, S.H. Cannabinoids and Bone: Friend or Foe? Calcif. Tissue Int. 2010, doi: 10.1007/s00223-010-9378-8.
4. Ahrens, P.B.; Solursh, M.; Reiter, R.S. Stage-related capacity for limb chondrogenesis in cell culture. Dev. Biol. 1977, 60, 69-82.
5. Guilak, F.; Awad, H.A.; Fermor, B.; Leddy, H.A.; Gimble, J.M. Adipose-derived adult stem cells for cartilage tissue engineering. Biorheology 2004, 41, 389-399.
6. Mbvundula, E.C.; Bunning, R.A.; Rainsford, K.D. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem. Pharmacol. 2005, 69, 635-640.
7. Mbvundula, E.C.; Bunning, R.A.; Rainsford, K.D. Arthritis and cannabinoids: HU-210 and Win55,212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in vitro. J. Pharm. Pharmacol. 2006, 58, 351-358.
8. Bidinger, B.; Torres, R.; Rossetti, R.G.; Brown, L.; Beltre, R.; Burstein, S.; Lian, J.B.; Stein, G.S.; Zurier, R.B. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin. Immunol. 2003, 108, 95-102.
9. Johnson, D.R.; Stebulis, J.A.; Rossetti, R.G.; Burstein, S.H.; Zurier, R.B. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J. Cell. Biochem. 2007, 100, 184-190.
10. Richardson, D.; Pearson, R.G.; Kurian, N.; Latif, M.L.; Garle, M.J.; Barrett, D.A.; Kendall, D.A.; Scammell, B.E.; Reeve, A.J.; Chapman, V. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther. 2008, 10, R43.
11. McDougall, J.J.; Yu, V.; Thomson, J. In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. Br. J. Pharmacol. 2008, 153, 358-366.
12. Reddi, A.H. Morphogenesis and tissue engineering of bone and cartilage: inductive signals, stem cells, and biomimetic biomaterials. Tissue Eng. 2000, 6, 351-359.
13. Nesic, D.; Whiteside, R.; Brittberg, M.; Wendt, D.; Martin, I.; Mainil-Varlet, P. Cartilage tissue engineering for degenerative joint disease. Adv. Drug Deliv. Rev. 2006, 58, 300-322.
14. Lu, L.; Zhu, X.; Valenzuela, R.G.; Currier, B.L.; Yaszemski, M.J. Biodegradable polymer scaffolds for cartilage tissue engineering. Clin. Orthop. Relat. Res. 2001, S251-S270.
15. Richter, W. Mesenchymal stem cells and cartilage in situ regeneration. J. Intern. Med. 2009, 266, 390-405.
16. Grimshaw, M.J.; Mason, R.M. Bovine articular chondrocyte function in vitro depends upon oxygen tension. Osteoarthritis Cartilage 2000, 8, 386-392.
17. Malda, J.; Martens, D.E.; Tramper, J.; van Blitterswijk, C.A.; Riesle, J. Cartilage tissue engineering: controversy in the effect of oxygen. Crit. Rev. Biotechnol. 2003, 23, 175-194.
18. Marcus, R.E.; Srivastava, V.M. Effect of low oxygen tensions on glucose-metabolizing enzymes in cultured articular chondrocytes. Proc. Soc. Exp. Biol. Med. 1973, 143, 488-491.
19. Brighton, C.T.; Heppenstall, R.B. Oxygen tension of the epiphyseal plate distal to an arteriovenous fistula. Clin. Orthop. Relat. Res. 1971, 80, 167-173.
20. Brittberg, M.; Tallheden, T.; Sjogren-Jansson, B.; Lindahl, A.; Peterson, L. Autologous chondrocytes used for articular cartilage repair: an update. Clin. Orthop. Relat. Res. 2001, S337-S348.
21. Haselgrove, J.C.; Shapiro, I.M.; Silverton, S.F. Computer modeling of the oxygen supply and demand of cells of the avian growth cartilage. Am. J. Physiol. 1993, 265, C497-C506.
22. Shum, L.; Nuckolls, G. The life cycle of chondrocytes in the developing skeleton. Arthritis Res. 2002, 4, 94-106.
23. DeLise, A.M.; Fischer, L.; Tuan, R.S. Cellular interactions and signaling in cartilage development. Osteoarthritis Cartilage 2000, 8, 309-334.
24. Sandell, L.J.; Adler, P. Developmental patterns of cartilage. Front. Biosci. 1999, 4, D731-D742.
25. Goldberg, V.M.; Caplan, A.I. Biological resurfacing: an alternative to total joint arthroplasty. Orthopedics 1994, 17, 819-821.
26. Mithoefer, K.; McAdams, T.; Williams, R.J.; Kreuz, P.C.; Mandelbaum, B.R. Clinical efficacy of the microfracture technique for articular cartilage repair in the knee: an evidence-based systematic analysis. Am. J. Sports Med. 2009, 37, 2053-2063.
27. Steadman, J.R.; Rodkey, W.G.; Briggs, K.K.; Rodrigo, J.J. The microfracture technic in the management of complete cartilage defects in the knee joint. Orthopade 1999, 28, 26-32.
28. Steadman, J.R.; Rodkey, W.G.; Briggs, K.K. Microfracture to treat full-thickness chondral defects: surgical technique, rehabilitation, and outcomes. J. Knee. Surg. 2002, 15, 170-176.
29. Kon, E.; Delcogliano, M.; Filardo, G.; Montaperto, C.; Marcacci, M. Second generation issues in cartilage repair. Sports Med. Arthrosc. 2008, 16, 221-229.
30. McNickle, A.G.; Provencher, M.T.; Cole, B.J. Overview of existing cartilage repair technology. Sports Med. Arthrosc. 2008, 16, 196-201.
31. Richter, W. Cell-based cartilage repair: illusion or solution for osteoarthritis. Curr. Opin. Rheumatol. 2007, 19, 451-456.
32. Pertwee, R.G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005, 7, E625-E654.
33. Pertwee, R.G. Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol. 2005, 1-51.
34. Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin, B.R.; Mechoulam, R.; Pertwee, R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54, 161-202.
35. Walker, J.M.; Hohmann, A.G. Cannabinoid mechanisms of pain suppression. Handb. Exp. Pharmacol. 2005, 168, 509-554.
36. Goutopoulos, A.; Makriyannis, A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol. Ther. 2002, 95, 103-117.
37. Onaivi, E.S.; Ishiguro, H.; Gong, J.P.; Patel, S.; Perchuk, A.; Meozzi, P.A.; Myers, L.; Mora, Z.; Tagliaferro, P.; Gardner, E.; Brusco, A.; Akinshola, B.E.; Liu, Q.R.; Hope, B.; Iwasaki, S.; Arinami, T.; Teasenfitz, L.; Uhl, G.R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. NY Acad. Sci. 2006, 1074, 514-536.
38. De Petrocellis, L.; Di Marzo, V. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J. Neuroimmune Pharmacol. 2010, 5, 103-121.
39. Scutt, A.; Williamson, E.M. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif. Tissue Int. 2007, 80, 50-59.
40. Fowler, C.J.; Rojo, M.L.; Rodriguez-Gaztelumendi, A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp. Neurol. 2010, 224, 37-47.
41. Steinmeyer, J.; Daufeldt, S. Pharmacological influence of antirheumatic drugs on proteoglycans from interleukin-1 treated articular cartilage. Biochem. Pharmacol. 1997, 53, 1627-1635.
42. Cawston, T. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol. Med. Today 1998, 4, 130-137.
43. Steinmeyer, J.; Daufeldt, S.; Kalbhen, D.A. The proteoglycan metabolism, morphology and viability of articular cartilage treated with a synthetic matrix metalloproteinase inhibitor. Res. Exp. Med. (Berl.) 1997, 197, 63-79.
44. Temenoff, J.S.; Mikos, A.G. Review: tissue engineering for regeneration of articular cartilage. Biomaterials 2000, 21, 431-440.
45. Buckwalter, J.A.; Mankin, H.J. Articular cartilage: tissue design and chondrocyte-matrix interactions. Instr. Course Lect. 1998, 47, 477-486.
46. Cohen, N.P.; Foster, R.J.; Mow, V.C. Composition and dynamics of articular cartilage: structure, function, and maintaining healthy state. J. Orthop. Sports Phys. Ther. 1998, 28, 203-215.
47. Friedenstein, A.J.; Piatetzky, S., II; Petrakova, K.V. Osteogenesis in transplants of bone marrow cells. J. Embryol. Exp. Morphol. 1966, 16, 381-390.
48. Friedenstein, A.J.; Chailakhjan, R.K.; Lalykina, K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970, 3, 393-403.
49. Owen, M. Marrow stromal stem cells. J. Cell Sci. 1988, 10, 63-76.
50. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; Marshak, D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, 143-147.
51. Barry, F.P.; Murphy, J.M. Mesenchymal stem cells: clinical applications and biological characterization. Int. J. Biochem. Cell Biol. 2004, 36, 568-584.
52. Lin, G.; Garcia, M.; Ning, H.; Banie, L.; Guo, Y.L.; Lue, T.F.; Lin, C.S. Defining stem and progenitor cells within adipose tissue. Stem Cells Dev. 2008, 17, 1053-1063.
53. De Bari, C.; Dell'Accio, F.; Tylzanowski, P.; Luyten, F.P. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001, 44, 1928-1942.
54. Barry, F.P. Biology and clinical applications of mesenchymal stem cells. Birth Defects Res. C Embryo Today 2003, 69, 250-256.
55. Barry, F.; Boynton, R.E.; Liu, B.; Murphy, J.M. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp. Cell Res. 2001, 268, 189-200.
56. Barry, F.; Boynton, R.; Murphy, M.; Haynesworth, S.; Zaia, J. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2001, 289, 519-524.
57. Bruder, S.P.; Jaiswal, N.; Ricalton, N.S.; Mosca, J.D.; Kraus, K.H.; Kadiyala, S. Mesenchymal stem cells in osteobiology and applied bone regeneration. Clin. Orthop. Relat. Res. 1998, S247-S256.
58. Bruder, S.P.; Kraus, K.H.; Goldberg, V.M.; Kadiyala, S. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. J. Bone Joint Surg. Am. 1998, 80, 985-996.
59. Digirolamo, C.M.; Stokes, D.; Colter, D.; Phinney, D.G.; Class, R.; Prockop, D.J. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br. J. Haematol. 1999, 107, 275-281.
60. Bunting, K.D.; Hawley, R.G. Integrative molecular and developmental biology of adult stem cells. Biol. Cell 2003, 95, 563-578.
61. Salem, H.K.; Thiemermann, C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010, 28, 585-596.
62. Bianco, P.; Riminucci, M.; Gronthos, S.; Robey, P.G. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 2001, 19, 180-192.
63. Kanichai, M.; Ferguson, D.; Prendergast, P.J.; Campbell, V.A. Hypoxia promotes chondrogenesis in rat mesenchymal stem cells: a role for AKT and hypoxia-inducible factor (HIF)-1alpha. J. Cell Physiol. 2008, 216, 708-715.
64. McMahon, L.A.; Reid, A.J.; Campbell, V.A.; Prendergast, P.J. Regulatory effects of mechanical strain on the chondrogenic differentiation of MSCs in a collagen-GAG scaffold: experimental and computational analysis. Ann. Biomed. Eng. 2008, 36, 185-194.
65. Sekiya, I.; Vuoristo, J.T.; Larson, B.L.; Prockop, D.J. In vitro cartilage formation by human adult stem cells from bone marrow stroma defines the sequence of cellular and molecular events during chondrogenesis. Proc. Natl. Acad. Sci. USA 2002, 99, 4397-4402.
66. Chen, C.W.; Tsai, Y.H.; Deng, W.P.; Shih, S.N.; Fang, C.L.; Burch, J.G.; Chen, W.H.; Lai, W.F. Type I and II collagen regulation of chondrogenic differentiation by mesenchymal progenitor cells. J. Orthop. Res. 2005, 23, 446-453.
67. Pistoia, V.; Raffaghello, L. Potential of mesenchymal stem cells for the therapy of autoimmune diseases. Expert Rev. Clin. Immunol. 2010, 6, 211-218.
68. Ross, R.A.; Brockie, H.C.; Stevenson, L.A.; Murphy, V.L.; Templeton, F.; Makriyannis, A.; Pertwee, R.G. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 1999, 126, 665-672.
69. McPartland, J.M. Expression of the endocannabinoid system in fibroblasts and myofascial tissues. J. Bodyw. Mov. Ther. 2008, 12, 169-182.
70. Idris, A.I.; Sophocleous, A.; Landao-Bassonga, E.; Canals, M.; Milligan, G.; Baker, D.; van't Hof, R.J.; Ralston, S.H. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab. 2009, 10, 139-147.
71. Whyte, L.S.; Ryberg, E.; Sims, N.A.; Ridge, S.A.; Mackie, K.; Greasley, P.J.; Ross, R.A.; Rogers, M.J. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. USA 2009, 106, 16511-16516.
72. Stebulis, J.A.; Johnson, D.R.; Rossetti, R.G.; Burstein, S.H.; Zurier, R.B. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 2008, 83, 666-670.
73. Burstein, S.H. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr. Pharm. Des. 2000, 6, 1339-1345.
74. Malfait, A.M.; Gallily, R.; Sumariwalla, P.F.; Malik, A.S.; Andreakos, E.; Mechoulam, R.; Feldmann, M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 2000, 97, 9561-9566.
75. Zurier, R.B.; Sun, Y.P.; George, K.L.; Stebulis, J.A.; Rossetti, R.G.; Skulas, A.; Judge, E.; Serhan, C.N. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB J. 2009, 23, 1503-1509.
76. Aguado, T.; Romero, E.; Monory, K.; Palazuelos, J.; Sendtner, M.; Marsicano, G.; Lutz, B.; Guzman, M.; Galve-Roperh, I. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J. Biol. Chem. 2007, 282, 23892-23898.
77. Berghuis, P.; Rajnicek, A.M.; Morozov, Y.M.; Ross, R.A.; Mulder, J.; Urban, G.M.; Monory, K.; Marsicano, G.; Matteoli, M.; Canty, A.; Irving, A.J.; Katona, I.; Yanagawa, Y.; Rakic, P.; Lutz, B.; Mackie, K.; Harkany, T. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 2007, 316, 1212-1216.
78. McPartland, J.M.; Skinner, E. The biodynamic model of osteopathy in the cranial field. Explore (NY) 2005, 1, 21-32.
79. Zhang, F.; Tsai, S.; Kato, K.; Yamanouchi, D.; Wang, C.; Rafii, S.; Liu, B.; Kent, K.C. Transforming growth factor-beta promotes recruitment of bone marrow cells and bone marrowderived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J. Biol. Chem. 2009, 284, 17564-17574.